×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. I consent to receive medical updates and communications from eMediNexus, it's parent company IJCP and its industry partners.

PCSK9 Inhibitors in Diabetic Dyslipidemia

  985 Views

Prof Sudarshan Ramachandran, UK    26 November 2018

  1. Despite recent debate, the evidence for the lipid hypothesis still remains strong.
  2. PCSK9 inhibitors are third-line LDL-C lowering agents in the UK. The efficacy is similar in patients with or without type 2 diabetes. No increase in new-onset diabetes is evident at this point.
  3. The FOURIER and ODYSSEY OUTCOMES randomized controlled studies show-lowering of CVD in keeping with the lipid hypothesis.
  4. Outpatient data shows that similar LDL-C reductions (55%) can be seen with both PCSK9 inhibitors - Evolocumab and alirocumab. Considerable variation exists in the LDL-C reduction (21-83%) in our series.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.